Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
Regeneron Pharmaceuticals announced that the FDA has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt), a bispecific antibody treatment for adult patients with relapsed or refractory ...
The Food and Drug Administration on Thursday approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss. The drugmaker said it will offer the drug for free to U.S. patients.
A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.
President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative. The deal ...
The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results